Our data show that low baseline testosterone levels, visual field defects, and pituitary hormone deficiency are predictors of the persistence of hypogonadism within the first year following prolactin normalization, a finding that may aid in identifying patients who are suitable for testosterone replacement therapy [33]. Here, PRL is linked to hypogonadism.